Harvard Apparatus Regenerative Technology Inc
For the period ended Sep 30, 2024. Filed Nov 13, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 13, 2024
HRGNStored price and day change unavailable
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ (Deficit) Equity (Unaudited)
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ (DEFICIT) EQUITY
(in thousands, except share data)
| Series E Convertible Preferred · Number of Common Shares · Common · Additional Paid-in · Accumulated · Accumulated Other Comprehensive · Total Stockholders’ (Deficit) | ||||||||
|---|---|---|---|---|---|---|---|---|
| Stock · Outstanding · Stock · Capital · Deficit · Loss · Equity | ||||||||
| Balance at July 1, 2024 | - | $— | 14,315,091 | $143 | $96,073 | $(96,484) | $(22) | $(290) |
| Share-based compensation | — | — | — | 562 | — | — | 562 | |
| Issuance of common stock | — | 1,388,888 | 14 | 4,986 | — | — | 5,000 | |
| Issuance of common stock from exercise of warrants | 215,000 | 2 | 428 | 430 | ||||
| Net loss | - | — | — | — | — | (1,860) | — | (1,860) |
| Other comprehensive loss | — | — | — | — | — | (2) | (2) | |
| Balance at September 30, 2024 | - | $— | 15,918,979 | $159 | $102,049 | $(98,344) | $(24) | $3,840 |
| Number of Common Shares | Common | Additional Paid-in | Accumulated | Total Stockholders’ | |
|---|---|---|---|---|---|
| Outstanding | Stock | Capital | Deficit | Equity | |
| Balance at July 1, 2023 | 13,882,060 | $139 | $92,172 | $(88,515) | $3,796 |
| Share-based compensation expense | — | — | 535 | — | 535 |
| Net loss | — | — | — | (1,615) | (1,615 |
| Balance at September 30, 2023 | 13,882,060 | $139 | $92,707 | $(90,130) | $2,716 |
| Series E Convertible Preferred | Number of Common Shares | Common | Additional Paid-in | Accumulated | Accumulated Other Comprehensive | Total Stockholders’ | |
|---|---|---|---|---|---|---|---|
| Stock | Outstanding | Stock | Capital | Deficit | Loss | Equity | |
| Balance at January 1, 2024 | $— | 13,947,324 | $139 | $93,463 | $(91,956) | $— | $1,646 |
| Share-based compensation | — | — | — | 1,694 | — | — | 1,694 |
| Issuance of common stock | — | 1,756,655 | 18 | 6,464 | — | — | 6,482 |
| Issuance of common stock from exercise of warrants | 215,000 | 2 | 428 | 430 | |||
| Net loss | — | — | — | — | (6,388) | — | (6,388) |
| Other comprehensive loss | — | — | — | — | — | (24) | (24) |
| Balance at September 30, 2024 | $— | 15,918,979 | $159 | $102,049 | $(98,344) | $(24) | $3,840 |
| Series E Convertible Preferred | Number of Common Shares | Common | Additional Paid-in | Accumulated | Total Stockholders’ (Deficit) | |
|---|---|---|---|---|---|---|
| Stock | Outstanding | Stock | Capital | Deficit | Equity | |
| Balance at January 1, 2023 | $4,180 | 12,174,467 | $122 | $79,698 | $(83,011) | $(3,191) |
| Preferred stock dividends | 77 | — | — | (77) | — | (77) |
| Conversion of preferred stock for common stock | (4,257) | 706,626 | 7 | 4,250 | — | 4,257 |
| Issuance of common stock, net of offering costs | — | 1,000,967 | 10 | 5,982 | — | 5,992 |
| Share-based compensation expense | — | — | — | 2,854 | — | 2,854 |
| Net loss | — | — | — | — | (7,119) | (7,119) |
| Balance at September 30, 2023 | $— | 13,882,060 | $139 | $92,707 | $(90,130) | $2,716 |
See accompanying notes to unaudited condensed consolidated financial statements
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.